These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32789500)

  • 41. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
    Voysey M; Pollard AJ
    Lancet; 2020 Nov; 396(10261):1486-1487. PubMed ID: 33160565
    [No Abstract]   [Full Text] [Related]  

  • 42. Covid-19: The Pandemic of Our Time.
    Murphy JFA
    Ir Med J; 2020 Apr; 113(4):46. PubMed ID: 32267942
    [No Abstract]   [Full Text] [Related]  

  • 43. Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond.
    Kar S; Islam R
    Bioanalysis; 2020 Sep; 12(17):1199-1203. PubMed ID: 32453605
    [No Abstract]   [Full Text] [Related]  

  • 44. COVID-19 shot protects monkeys.
    Cohen J
    Science; 2020 May; 368(6490):456-457. PubMed ID: 32355008
    [No Abstract]   [Full Text] [Related]  

  • 45. After A COVID-19 Vaccine: Collaboration Or Competition?
    Meyer H
    Health Aff (Millwood); 2020 Nov; 39(11):1856-1860. PubMed ID: 32986500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19 and mRNA Vaccines-First Large Test for a New Approach.
    Abbasi J
    JAMA; 2020 Sep; 324(12):1125-1127. PubMed ID: 32880613
    [No Abstract]   [Full Text] [Related]  

  • 47. Adverse Consequences of Rushing a SARS-CoV-2 Vaccine: Implications for Public Trust.
    Trogen B; Oshinsky D; Caplan A
    JAMA; 2020 Jun; 323(24):2460-2461. PubMed ID: 32453392
    [No Abstract]   [Full Text] [Related]  

  • 48. Building Trust to Achieve Confidence in COVID-19 Vaccines.
    Opel DJ; Salmon DA; Marcuse EK
    JAMA Netw Open; 2020 Oct; 3(10):e2025672. PubMed ID: 33079194
    [No Abstract]   [Full Text] [Related]  

  • 49. Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
    Logunov DY; Dolzhikova IV; Tukhvatullin AI; Shcheblyakov DV
    Lancet; 2020 Oct; 396(10256):e54-e55. PubMed ID: 32971043
    [No Abstract]   [Full Text] [Related]  

  • 50. COVID-19 vaccines: early success and remaining challenges.
    Bar-Zeev N; Inglesby T
    Lancet; 2020 Sep; 396(10255):868-869. PubMed ID: 32896290
    [No Abstract]   [Full Text] [Related]  

  • 51. The Covid-19 Vaccine-Development Multiverse.
    Heaton PM
    N Engl J Med; 2020 Nov; 383(20):1986-1988. PubMed ID: 32663910
    [No Abstract]   [Full Text] [Related]  

  • 52. Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials: Too Risky, Too Soon.
    Dawson L; Earl J; Livezey J
    J Infect Dis; 2020 Jul; 222(3):514-516. PubMed ID: 32496536
    [No Abstract]   [Full Text] [Related]  

  • 53. China's coronavirus vaccine shows military's growing role in medical research.
    Lewis D
    Nature; 2020 Sep; 585(7826):494-495. PubMed ID: 32918053
    [No Abstract]   [Full Text] [Related]  

  • 54. A SARS-CoV-2 mRNA Vaccine - Preliminary Report.
    Schachar RA; Schachar IH
    N Engl J Med; 2020 Sep; 383(12):1190-1191. PubMed ID: 32813940
    [No Abstract]   [Full Text] [Related]  

  • 55. Unnecessary hesitancy on human vaccine tests.
    Eyal N
    Science; 2020 Jul; 369(6500):150-151. PubMed ID: 32646991
    [No Abstract]   [Full Text] [Related]  

  • 56. Unnecessary hesitancy on human vaccine tests-Response.
    Shah SK; Miller FG; Darton TC; Duenas D; Emerson C; Lynch HF; Jamrozik E; Jecker NS; Kamuya D; Kapulu M; Kimmelman J; MacKay D; Memoli MJ; Murphy SC; Palacios R; Richie TL; Roestenberg M; Saxena A; Saylor K; Selgelid MJ; Vaswani V; Rid A
    Science; 2020 Jul; 369(6500):151. PubMed ID: 32646992
    [No Abstract]   [Full Text] [Related]  

  • 57. Covid-19 elimination: consider population level effects of vaccine.
    Payne N
    BMJ; 2020 Oct; 371():m3889. PubMed ID: 33023934
    [No Abstract]   [Full Text] [Related]  

  • 58. Challenge Trials-Could Deliberate Coronavirus Exposure Hasten Vaccine Development?
    Rubin R
    JAMA; 2020 Jul; 324(1):12-14. PubMed ID: 32496545
    [No Abstract]   [Full Text] [Related]  

  • 59. Encouraging results from phase 1/2 COVID-19 vaccine trials.
    Bar-Zeev N; Moss WJ
    Lancet; 2020 Aug; 396(10249):448-449. PubMed ID: 32702300
    [No Abstract]   [Full Text] [Related]  

  • 60. Aggregating data from COVID-19 trials.
    Ogburn EL; Bierer BE; Brookmeyer R; Choirat C; Dean NE; De Gruttola V; Ellenberg SS; Halloran ME; Hanley DF; Lee JK; Wang R; Scharfstein DO
    Science; 2020 Jun; 368(6496):1198-1199. PubMed ID: 32527823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.